MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$3,705,144
Unit: Dollar
Positive Cash Flow Breakdown
    • Non-cash operating lease cost
    • Stock-based compensation expense
    • Fair value of shares issued for ...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Other prepaid expenses
    • Accounts payable and accrued exp...
    • Others
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-1,987,608
-6,009,520
-
-
Research and development costs
-
-
-
0
Net loss
-
-
-1,980,398
-1,485,228
Non-cash lease expense for right-of-use asset
-
61,695
-
-
Non-cash operating lease cost
122,553
-
-
-
General and administrative costs
-
-
776,611
367,737
Stock-based compensation expense
82,176
1,388,322
-
-
Common stock issued for services
-
126,900
44,711
-
Unrealized gain (loss) on digital assets
-
-
-182,887
-
Realized loss on digital assets
-
904,394
-
-
Fair value of shares issued for services
53,400
-
-
-
Prepaid insurance
29,349
-2,808
14,893
-6,301
Other prepaid expenses
56,244
-17,014
-26,104
2,290
Accounts payable and accrued expenses
-45,401
285,115
59,218
36,443
Research and development contract liabilities
6,297
-3,017
-20,992
21,069
Advances on research and development contract services
-
-
-
0
Operating lease liability
22,813
-
-
-
Net cash used in operating activities
-1,831,363
-1,087,898
-926,752
-1,055,968
Purchase of digital assets
-
0
2,637,360
-
Cash paid for liora investment
-
440,000
-
-
Capitalized costs for light equipment
24,859
95,102
-
-
Net cash used in investing activities
-24,859
-535,102
-2,637,360
-
Proceeds from sale of securities in registered direct offerings, net of offering costs
-
3,841,997
1,330,812
914,228
Proceeds from sale of securities in registered private placement, net of offering costs
-
0
4,178,162
-
Payment of deferred offering costs
-
-
-
10,000
Exercise of common stock warrants
-
1
45,800
-
Net cash provided by financing activities
-
3,841,998
5,564,774
904,228
Net change in cash
-
4,067,920
-
-
Net increase (decrease)
-3,705,144
-
2,000,662
-151,740
Cash - beginning of period
5,106,872
2,887,874
1,038,952
-
Cash - end of period
3,250,650
5,106,872
2,887,874
-
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net increase(decrease)-$3,705,144 Non-cash operating leasecost$122,553 Stock-based compensationexpense$82,176 Fair value of sharesissued for services$53,400 Operating lease liability$22,813 Research and developmentcontract liabilities$6,297 something is missing-$1,848,922 Net cash used inoperating activities-$1,831,363 Net cash used ininvesting activities-$24,859 Canceled cashflow$287,239 Net loss-$1,987,608 Capitalized costs for lightequipment$24,859 Other prepaidexpenses$56,244 Accounts payable andaccrued expenses-$45,401 Prepaid insurance$29,349

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)